Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 1/20 | 0.33 |
| ▸ | RXRA | P19793 | 8/20 | 0.32 |
| ▸ | GYS1 | P13807 | 1/20 | 0.32 |
| ▸ | RXRB | P28702 | 8/20 | 0.31 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.31 |
| ▸ | RXRG | P48443 | 5/20 | 0.31 |
| ▸ | RORC | P51449 | 1/20 | 0.30 |
| ▸ | PTGIR | P43119 | 1/20 | 0.30 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | PPARG | P37231 | 1/20 | 0.30 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23211050 | 0.91 | SCN9A (0.32) | SCN9AALOX5 | |
| SCHEMBL29907073 | 0.91 | SCN9A (0.32) | SCN9AALOX5 | |
| SCHEMBL23211084 | 0.90 | GYS1 (0.33) | RXRAGYS1RXRBMRGPRX4RXRG | |
| SCHEMBL23210814 | 0.85 | AKT1 (0.36) | SCN9ARXRAGYS1RORCPTGIR | |
| SCHEMBL29907209 | 0.81 | TNF (0.36) | GYS1PTGIRPTGDRALOX5 | |
| SCHEMBL23211054 | 0.81 | TNF (0.36) | GYS1PTGIRPTGDRALOX5 | |
| SCHEMBL23211042 | 0.77 | MEN1 (0.37) | RXRARXRBRORCNPC1RAB9A | |
| SCHEMBL23211071 | 0.76 | STAT3 (0.33) | — | |
| SCHEMBL29907072 | 0.76 | STAT3 (0.33) | — | |
| SCHEMBL30308837 | 0.76 | STAT3 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230338389-A1 | BICYCLIC HETEROCYCLES AS FGFR INHIBITORS | INCYTE CORPORATION | 2023-10-26 | — | — | US | disclosed |
| US-11607416-B2 | Bicyclic heterocycles as FGFR inhibitors | INCYTE CORPORATION (US) | 2023-03-21 | — | — | US | disclosed |
| US-20210106588-A1 | BICYCLIC HETEROCYCLES AS FGFR INHIBITORS | INCYTE CORPORATION | 2021-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210106588-A1 | BICYCLIC HETEROCYCLES AS FGFR INHIBITORS | FGFR1, FGFR3, FGFR2 | SCN9A 4428/4885RXRA 1292/4885GYS1 4157/4885 |
| US-11607416-B2 | Bicyclic heterocycles as FGFR inhibitors | FGFR1, FGFR3, FGFR2 | SCN9A 4428/4885RXRA 1292/4885GYS1 4157/4885 |
| US-20230338389-A1 | BICYCLIC HETEROCYCLES AS FGFR INHIBITORS | FGFR1, FGFR3, FGFR2 | SCN9A 4428/4885RXRA 1292/4885GYS1 4157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.